Real Estate -
Real Estate - Services - NASDAQ - US
$ 8.36
15.3 %
$ 9.15 M
Market Cap
-0.42
P/E
1. INTRINSIC VALUE
Balance Sheet
Avalon GloboCare Corp.
| Current Assets | 851 K |
| Cash & Short-Term Investments | 285 K |
| Receivables | 235 K |
| Other Current Assets | 331 K |
| Non-Current Assets | 19.7 M |
| Long-Term Investments | 12.1 M |
| PP&E | 166 K |
| Other Non-Current Assets | 7.47 M |
| Current Liabilities | 6.76 M |
| Accounts Payable | 0 |
| Short-Term Debt | 2.18 M |
| Other Current Liabilities | 4.58 M |
| Non-Current Liabilities | 6.45 M |
| Long-Term Debt | 6.45 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Avalon GloboCare Corp.
| Revenue | 1.26 M |
| Cost Of Revenue | 1.02 M |
| Gross Profit | 238 K |
| Operating Expenses | 16 M |
| Operating Income | -15.8 M |
| Other Expenses | 953 K |
| Net Income | -16.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Avalon GloboCare Corp.
| Net Income | -16.7 M |
| Depreciation & Amortization | 330 K |
| Capital Expenditures | -22.2 K |
| Stock-Based Compensation | 1.18 M |
| Change in Working Capital | -35.1 K |
| Others | 8.69 M |
| Free Cash Flow | -6.53 M |
Wall Street Analysts Price Targets
Avalon GloboCare Corp.
ALBT has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ALBT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Avalon GloboCare Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
4 years ago
Apr 01, 2020
|
Bought
1 M USD
|
Lu Wenzhao
director, 10 percent owner:
|
+ 645161
|
1.55 USD |
|
4 years ago
Apr 01, 2020
|
Bought
1 M USD
|
Lu Wenzhao
director, 10 percent owner:
|
+ 645161
|
1.55 USD |
|
5 years ago
Jun 07, 2019
|
Bought
27.6 K USD
|
Lu Wenzhao
director, 10 percent owner:
|
+ 15000
|
1.84 USD |
|
5 years ago
Apr 18, 2019
|
Bought
27.6 K USD
|
Lu Wenzhao
Director
|
+ 15000
|
1.84 USD |
|
5 years ago
Apr 18, 2019
|
Bought
42.6 K USD
|
Lu Wenzhao
Director
|
+ 21000
|
2.03 USD |
|
5 years ago
Jun 06, 2019
|
Bought
42.6 K USD
|
Lu Wenzhao
director, 10 percent owner:
|
+ 21000
|
2.03 USD |
|
5 years ago
Apr 18, 2019
|
Bought
2 M USD
|
Lu Wenzhao
director, 10 percent owner:
|
+ 2000000
|
1 USD |
|
5 years ago
Apr 18, 2019
|
Bought
2 M USD
|
Lu Wenzhao
director, 10 percent owner:
|
+ 2000000
|
1 USD |
|
7 years ago
Dec 15, 2017
|
Bought
260 USD
|
Sukel Steven Philip
Director
|
+ 100
|
2.6 USD |
|
7 years ago
Dec 15, 2017
|
Bought
600 USD
|
Sukel Steven Philip
Director
|
+ 300
|
2 USD |
|
7 years ago
Dec 15, 2017
|
Bought
1.6 K USD
|
Sukel Steven Philip
Director
|
+ 600
|
2.67 USD |
|
7 years ago
Nov 20, 2017
|
Bought
900 USD
|
Sukel Steven Philip
Director
|
+ 500
|
1.8 USD |
|
7 years ago
Nov 20, 2017
|
Bought
1.62 K USD
|
Sukel Steven Philip
Director
|
+ 900
|
1.8 USD |
|
7 years ago
Nov 20, 2017
|
Bought
995 USD
|
Sukel Steven Philip
Director
|
+ 500
|
1.99 USD |
|
7 years ago
Nov 20, 2017
|
Bought
567 USD
|
Sukel Steven Philip
Director
|
+ 300
|
1.89 USD |
|
7 years ago
Nov 20, 2017
|
Bought
190 USD
|
Sukel Steven Philip
Director
|
+ 100
|
1.9 USD |
|
7 years ago
Nov 20, 2017
|
Bought
594 USD
|
Sukel Steven Philip
Director
|
+ 300
|
1.98 USD |
|
7 years ago
Nov 20, 2017
|
Bought
2.92 K USD
|
Sukel Steven Philip
Director
|
+ 1500
|
1.95 USD |
|
7 years ago
Nov 20, 2017
|
Bought
199 USD
|
Sukel Steven Philip
Director
|
+ 100
|
1.99 USD |
|
7 years ago
Nov 20, 2017
|
Bought
1.95 K USD
|
Sukel Steven Philip
Director
|
+ 1000
|
1.95 USD |
|
7 years ago
Nov 20, 2017
|
Bought
198 USD
|
Sukel Steven Philip
Director
|
+ 100
|
1.98 USD |
|
7 years ago
Apr 01, 2017
|
Bought
199 USD
|
Sukel Steven Philip
Director
|
+ 100
|
1.99 USD |
|
7 years ago
Apr 01, 2017
|
Bought
199 USD
|
Sukel Steven Philip
Director
|
+ 100
|
1.99 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.75 K USD
|
Sukel Steven Philip
Director
|
+ 1100
|
2.5 USD |
|
7 years ago
Apr 01, 2017
|
Bought
625 USD
|
Sukel Steven Philip
Director
|
+ 250
|
2.5 USD |
|
7 years ago
Apr 01, 2017
|
Bought
700 USD
|
Sukel Steven Philip
Director
|
+ 200
|
3.5 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.49 K USD
|
Sukel Steven Philip
Director
|
+ 815
|
3.05 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.1 K USD
|
Sukel Steven Philip
Director
|
+ 700
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.4 K USD
|
Sukel Steven Philip
Director
|
+ 750
|
3.2 USD |
|
7 years ago
Apr 01, 2017
|
Bought
650 USD
|
Sukel Steven Philip
Director
|
+ 200
|
3.25 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.44 K USD
|
Sukel Steven Philip
Director
|
+ 750
|
3.25 USD |
|
7 years ago
Apr 01, 2017
|
Bought
320 USD
|
Sukel Steven Philip
Director
|
+ 100
|
3.2 USD |
|
7 years ago
Apr 01, 2017
|
Bought
325 USD
|
Sukel Steven Philip
Director
|
+ 100
|
3.25 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2 K USD
|
Sukel Steven Philip
Director
|
+ 500
|
4 USD |
|
7 years ago
Apr 01, 2017
|
Bought
1.9 K USD
|
Sukel Steven Philip
Director
|
+ 500
|
3.8 USD |
|
7 years ago
Apr 01, 2017
|
Bought
1.8 K USD
|
Sukel Steven Philip
Director
|
+ 500
|
3.6 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.01 K USD
|
Sukel Steven Philip
Director
|
+ 600
|
3.35 USD |
|
7 years ago
Apr 01, 2017
|
Bought
359 USD
|
Sukel Steven Philip
Director
|
+ 100
|
3.59 USD |
|
7 years ago
Apr 01, 2017
|
Bought
708 USD
|
Sukel Steven Philip
Director
|
+ 200
|
3.54 USD |
|
7 years ago
Apr 01, 2017
|
Bought
339 USD
|
Sukel Steven Philip
Director
|
+ 100
|
3.39 USD |
|
7 years ago
Apr 01, 2017
|
Bought
334 USD
|
Sukel Steven Philip
Director
|
+ 100
|
3.34 USD |
|
7 years ago
Apr 01, 2017
|
Bought
1.58 K USD
|
Sukel Steven Philip
Director
|
+ 500
|
3.15 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.4 K USD
|
Sukel Steven Philip
Director
|
+ 800
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought
334 USD
|
Sukel Steven Philip
Director
|
+ 100
|
3.34 USD |
|
7 years ago
Apr 01, 2017
|
Bought
2.25 K USD
|
Sukel Steven Philip
Director
|
+ 750
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought
3 K USD
|
Sukel Steven Philip
Director
|
+ 1000
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought
295 USD
|
Sukel Steven Philip
Director
|
+ 100
|
2.95 USD |
|
7 years ago
Apr 01, 2017
|
Bought
600 USD
|
Sukel Steven Philip
Director
|
+ 200
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought
195 USD
|
Sukel Steven Philip
Director
|
+ 100
|
1.95 USD |
|
7 years ago
Apr 01, 2017
|
Bought
200 USD
|
Sukel Steven Philip
Director
|
+ 100
|
2 USD |
|
7 years ago
Apr 01, 2017
|
Bought
300 K USD
|
Sukel Steven Philip
Director
|
+ 200000
|
1.5 USD |
|
7 years ago
Apr 20, 2017
|
Sell 2.5 M
USD
|
Lu Wenzhao
director, 10 percent owner:
|
- 5000000
|
0.5 USD |
|
7 years ago
Apr 20, 2017
|
Sell 2.5 M
USD
|
Lu Wenzhao
Director
|
- 5000000
|
0.5 USD |
7. News
Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring.
globenewswire.com
- 3 months ago
Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with an exclusivity period of 120 days (the “Exclusivity Period”), during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the proposed strategic collaboration.
globenewswire.com
- 4 months ago
Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?
Avalon GloboCare (NASDAQ: ALBT ) stock is up on Wednesday alongside news of a new medical device being launched by Laboratory Services MSO. Laboratory Services MSO is preparing to launch its GeeWhiz External Condom Catheter in the third quarter of 2024.
investorplace.com
- 6 months ago
Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection
globenewswire.com
- 7 months ago
Avalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024
Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that the booth at the event in Austin “attracted a diverse group of potential clients and partners, including doctors, disease management companies, health and keto coaches, consumers, keto product manufacturers, and service providers interested in establishing a marketplace on our app and device.
proactiveinvestors.com
- 8 months ago
Why Is Avalon Globocare (ALBT) Stock Down 27% Today?
Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the company filed its Form 10-Q with the Securities and Exchange Commission (SEC).
investorplace.com
- 8 months ago
Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).
globenewswire.com
- 9 months ago
Avalon GloboCare launches KetoAir breathalyzer in the US
Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.
proactiveinvestors.com
- 10 months ago
Avalon GloboCare launches KetoAir breathalyzer in the US
Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.
proactiveinvestors.com
- 10 months ago
Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference
FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.
globenewswire.com
- 10 months ago
Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer
Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union. Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.
proactiveinvestors.com
- 11 months ago
Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union
FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.
globenewswire.com
- 11 months ago
8. Profile
Summary
Avalon GloboCare Corp. ALBT
COUNTRY
US
INDUSTRY
Real Estate - Services
MARKET CAP
$ 9.15 M
Dividend Yield
0.00%
Description
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Contact
4400 Route 9 South, Freehold, NJ, 07728
https://www.avalon-globocare.com
IPO
Date
March 27, 2018
Employees
4
Officers
Ms. Luisa Ingargiola
Chief Financial Officer
Ms. Meng Li
Chief Operating Officer & Secretary
Dr. David K. Jin M.D., Ph.D.
Chief Executive Officer, President & Director